inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 601–700 of 1,000
Reactive dirty fragments: implications for tuberculosis drug discovery
Gopal, P., & Dick, T. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2014.06.015 · Cited by 35
“ETH, less well studied, is activated by the mono-oxygenase EthA [23] and again curiously appears to inhibit InhA as its major target [24].”
BackgroundEvolution of Mycobacterium tuberculosis : New Insights into Pathogenicity and Drug Resistance
Boritsch, E. C., & Brosch, R. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0020-2016 · Cited by 36
“Low-level resistance, in turn, is associated with mutations in the NADH-dependent enoyl-acyl-carrier protein reductase InhA, involved in mycolic acid synthesis and the target of the drug (136).”
BackgroundA Novel Degradation Mechanism for Pyridine Derivatives in Alcaligenes faecalis JQ135
Qiu, J., Liu, B., Zhao, L., Zhang, Y., Cheng, D., Yan, X., Jiang, J., Hong, Q., & He, J. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.00910-18 · Cited by 32
Guy, C. S., Gibson, M. I., & Fullam, E. (2019) · Chemical Science · doi:10.1039/c9sc00415g · Cited by 33
Trehalose Conjugation Enhances Toxicity of Photosensitizers against Mycobacteria
Dutta, A. K., Choudhary, E., Wang, X., Záhorszká, M., Forbak, M., Lohner, P., Jessen, H. J., Agarwal, N., Korduláková, J., & Jessen‐Trefzer, C. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00962 · Cited by 34
“Isoniazid inhibits enoyl-ACP-reductase that participates in the synthesis of mycolic acids, 33 thus con fi rming mycolic acid content of 16-”
de Faria, C. F., Moreira, T., Lopes, P., Costa, H., Krewall, J. R., Barton, C. M., Santos, S., Goodwin, D. C., Machado, D., Viveiros, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112362 · Cited by 32
Lopez-Alvarez, R., Badillo-López, C., Cerna-Cortés, J. F., Castillo-Ramirez, I., Rivera-Gutiérrez, S., Helguera‐Repetto, A. C., Aguilar, D., Hernández‐Pando, R., Samper, S., & González-y-Merchand, J. A. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-82 · Cited by 34
The Genetics of Cell Wall Biosynthesis in Mycobacterium Tuberculosis
Goude, R., & Parish, T. (2008) · Future Microbiology · doi:10.2217/17460913.3.3.299 · Cited by 35
Tudó, G., González, J., Obama, R., Jm, T.-R., Franco, J. R., Espasa, M., Pr, S., Escaramís, G., Ascaso, C., García, A., et al. (2004) · PubMed · Cited by 33
Suzuki, Y., Katsukawa, C., Inoue, K., Yue Ping, Y. I. N., 田坂, 博., Noboru, U. E. B. A., & MAKINO, M. (1995) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi1970.69.413 · Cited by 32
Rafi, S. B., Cui, G., Song, K., Cheng, X., Tonge, P. J., & Simmerling, C. L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060222t · Cited by 32
Dussurget, O., Rodriguez, M., & Smith, I. (1998) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0011 · Cited by 32
Fitness of Mycobacterium tuberculosis Strains of the W-Beijing and Non-W-Beijing Genotype
von Groll, A., Martin, A., Stehr, M., Singh, M., Portaels, F., da Silva, P. E. A., & Palomino, J. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010191 · Cited by 36
“The most common mechanism associated with the acquisition of resistance to RMP is a mutation in the rpoB gene [21] and for INH are mutations in katG and the inhA operon [22,23].”
BackgroundUnraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis
Poulton, N. C., & Rock, J. M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.997283 · Cited by 40
“For example, many antitubercular compounds target envelope biosynthesis either directly (Banerjee et al., 1994; Goude et al., 2009) or indirectly (Stover et al.”
BackgroundChebaiki, M., Delfourne, E., Tamhaev, R., Danoun, S., Rodriguez, F., Hoffmann, P., Grosjean, E., Goncalves, F., Azéma, J., Pál, A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115646 · Cited by 33
Sharma, S. K., Kumar, G., Kapoor, M., & Surolia, A. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.191 · Cited by 31
Arai, M., Liu, L., Fujimoto, T., Setiawan, A., & Kobayashi, M. (2011) · Marine Drugs · doi:10.3390/md9060984 · Cited by 32
Islam, M. M., Tan, Y., Hameed, H. M. A., Liu, Z., Chhotaray, C., Liu, Y., Lu, Z., Cai, X., Tang, Y., Gao, Y., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.12.008 · Cited by 31
Klopman, G., Fercu, D., & Jacob, J. (1996) · Chemical Physics · doi:10.1016/0301-0104(95)00415-7 · Cited by 31
Pulse oximetry: Accuracy of methods of interpreting graphic summaries
Lafontaine, V. M., Ducharme, F. M., & Brouillette, R. T. (1996) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199602)21:2<121::aid-ppul7>3.0.co;2-u · Cited by 23
Mycobacteria: Genetics of Resistance and Implications for Treatment
Sander, P., & Böttger, E. C. (1999) · Chemotherapy · doi:10.1159/000007171 · Cited by 34
Collie, G. W., Clark, M., Keefe, A. D., Madin, A., Read, J. A., Rivers, E. L., & Zhang, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01861 · Cited by 35
Gut microbiota and tuberculosis
Liu, Y., Yang, L., Meskini, M., Goel, A., Opperman, M., Shyamal, S. S., Manaithiya, A., Xiao, M., Ni, R., An, Y., et al. (2025) · iMeta · doi:10.1002/imt2.70054 · Cited by 43
Design, synthesis and evaluation of antitubercular activity of Triclosan analogues
Cinu, T. A., Kar, S. S., Bairy, I., Varadaraj, B. G., Shenoy, V. P., & Shenoy, G. G. (2015) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2015.09.003 · Cited by 30
“Moreover, InhA has already been known as the molecular target of the frontline antitubercular drugs isoniazid and ethionamide (ETA) (Banerjee et al., 1994; Wang et al., 2007).”
BackgroundIdentifying co-targets to fight drug resistance based on a random walk model
Chen, L., Yeh, H., Yeh, C.-Y., Arias, C. R., & Soo, V. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-5 · Cited by 33
“The kasA genomic consists of five genes in an operon (fabD, acpM, kasA, kasB and accD6) and all of them encode for enzymes that are involved in the fatty acid biosynthesis pathway [46-49].”
BackgroundZimhony, O., Schwarz, A., Raitses‐Gurevich, M., Peleg, Y., Dym, O., Albeck, S., Burstein, Y., & Shakked, Z. (2015) · Biochemistry · doi:10.1021/bi501444e · Cited by 34
Reta, M. A., Alemnew, B. T. T., Abate, B. B., & Fourie, P. B. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.06.009 · Cited by 31
Molecular Modeling ofMycobacterium TuberculosisdUTpase: Docking and Catalytic Mechanism Studies
Ramalho, T. C., Caetano, M. S., Josa, D., Luz, G. H. P., Freitas, E. A., & da Cunha, E. F. F. (2011) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2011.10508617 · Cited by 30
Multidrug resistance in Mycobacterium tuberculosis
Heym, B., & Cole, S. T. (1997) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(96)00356-1 · Cited by 40
The use of macroarrays for the identification of MDR Mycobacterium tuberculosis
Brown, T. J., Herrera, L., Anthony, R. M., & Drobniewski, F. A. (2005) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2005.08.002 · Cited by 30
“tuberculosis, these include katG, mabA-inhA, oxyR-ahpC (Zhang et al., 1992; Banerjee et al., 1994; Sreevatsan et al., 1997).”
BackgroundMycobacterium marinum infection in Drosophila melanogaster for antimycobacterial activity assessment
Oh, C.-T., Moon, C., Choi, T.-H., Kim, B. S., & Jang, J. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks425 · Cited by 32
Tuberculosis In Australia: Bacteriologically confirmed cases and drug resistance, 2010
Lumb, R., Bastian, I., Gilpin, C., Jelfs, P. J., Keehner, T., & Sievers, A. S. (2008) · Communicable Diseases Intelligence · doi:10.33321/cdi.2008.32.2 · Cited by 30
Old and New TB Drugs: Mechanisms of Action and Resistance
Anastasia, S., & Petros, C. (2012) · InTech eBooks · doi:10.5772/30992 · Cited by 53
Pedgaonkar, G. S., Sridevi, J. P., Jeankumar, V. U., Saxena, S., Devi, P. B., Renuka, J., Yogeeswari, P., & Sriram, D. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.028 · Cited by 35
Rapid Prediction of Rifampin Susceptibility of Mycobacterium Tuberculosis
Ohno, H., Koga, H., Kuroita, T., Tomono, K., Ogawa, K., Yanagihara, K., Yamamoto, Y., Miyamoto, J., Tashiro, T., & KOHNO, S. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196115 · Cited by 30
Machado, K., SCHROEDER, E., Ruiz, D. D., Cohen, E. M., & de Souza, O. N. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-s4-s6 · Cited by 29
“InhA mutant strains have emerged almost at the same time that isoniazid (INH) was first launched in the market in the early 50 ’ s as a first line drug for the treatment of tuberculosis [44].”
BackgroundBiosynthesis of Galactan in Mycobacterium tuberculosis as a Viable TB Drug Target?
Konyariková, Z., Savková, K., Kozmon, S., & Mikušová, K. (2020) · Antibiotics · doi:10.3390/antibiotics9010020 · Cited by 35
“Isoniazid and ethambutol inhibit the production of mycolates [9] and arabinan polymer [10], respectively; however, no current drugs target the synthesis of the galactan core.”
BackgroundAn Insight on the Prospect of Quinazoline and Quinazolinone Derivatives as Anti-tubercular Agents
Kushwaha, N., Sahu, A., Mishra, J., Soni, A., & Dorwal, D. (2023) · Current Organic Synthesis · doi:10.2174/1570179420666230316094435 · Cited by 34
Amos, R. I. J., Gourlay, B. S., Yates, B. F., Schiesser, C. H., Lewis, T. W., & Smith, J. A. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26419f · Cited by 29
Elucidating Isoniazid Resistance Using Molecular Modeling
Wahab, H. A., Choong, Y. S., Ibrahim, P., Sadikun, A., & Scior, T. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8001342 · Cited by 31
Mechanisms of isoniazid resistance in Mycobacterium tuberculosis
Barry, C. E., Slayden, R. A., & Mdluli, K. E. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80028-9 · Cited by 33
Ho, Y. M., Sun, Y.-J., Wong, S. Y., & Lee, A. S. G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00433-09 · Cited by 33
“Clinical resistance to INH is widely known to be caused by mutations within the katG and inhA genes and the promoter region of inhA (2, 13, 18, 19, 25, 29).”
BackgroundFattorini, L., Li, B., Piersimoni, C., Tortoli, E., Xiao, Y., Santoro, C., Ricci, M. L., & Orefici, G. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.680 · Cited by 29
“Considering that the mechanisms of action of this drug are not yet fully elucidated (1), it could be interesting to investigate the activity of INH, in combination with other antimicrobial agents, such as CLA-AMI, in appropriate animal models.”
BackgroundSchami, A., Islam, M. N., Belisle, J. T., & Torrelles, J. B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1274175 · Cited by 34
Bioinformatics Identification of Drug Resistance-Associated Gene Pairs in Mycobacterium tuberculosis
Cui, Z.-J., Yang, Q., Zhang, H., Zhu, Q., & Zhang, Q. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091417 · Cited by 28
Thiede, J. M., Dillon, N. A., Howe, M. D., Aflakpui, R., Modlin, S. J., Hoffner, S., Valafar, F., Minato, Y., & Baughn, A. D. (2022) · mBio · doi:10.1128/mbio.00439-21 · Cited by 32
Design, synthesis of quinolinyl Schiff bases and azetidinones as enoyl ACP-reductase inhibitors
Joshi, S. D., More, U. A., Parkale, D., Aminabhavi, T. M., Gadad, A. K., Nadagouda, M. N., & Jawarkar, R. D. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1432-7 · Cited by 28
“MTB contains unique signature fatty acids, the mycolic acids, which are unusually long chain a-alkyl, b-hydroxy fatty acids of 60–90 carbons (Banerjee et al., 1994).”
BackgroundSynthesis and molecular modeling studies of novel pyrrole analogs as antimycobacterial agents
Joshi, S. D., More, U. A., Pansuriya, K., Aminabhavi, T. M., & Gadad, A. K. (2013) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2013.09.002 · Cited by 28
“In a critical review published recently, the existence of more than 3000 compounds based on the INH core was reported, about 66% of them being hydrazones (Ballell et al., 2005; Janin, 2007).”
InfluentialIdentification of novel antitubercular compounds through hybrid virtual screening approach
Muddassar, M., Jang, J. W., Gon, H. S., Cho, Y. S., Kim, E. E., Keum, K. C., Oh, T., Cho, S.-N., & Pae, A. N. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.010 · Cited by 30
Kamal, Ä., Shetti, R. V. C. R. N. C., Azeeza, S., Ahmed, S. K., Swapna, P., Reddy, A. M., Khan, I. A., Sharma, S., & Abdullah, S. T. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.07.015 · Cited by 28
Barletta, F., Otero, L., de Jong, B. C., Iwamoto, T., Arikawa, K., der Stuyft, P. V., Niemann, S., Merker, M., Uwizeye, C., Seas, C., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.03585-14 · Cited by 28
“, transmission of MDR-TB and acquired resistance due to ineffective TB treatment selecting for spontaneous mutations in specific genes associated with drug resistance (13, 14).”
BackgroundChen, P., & Bishai, W. R. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5099-5106.1998 · Cited by 28
“Finally, mutations in inhA, which encodes a fatty acyl enoyl reductase that is a component of fatty acid synthase type II systems, have been shown to cause INH resistance in Mycobacterium smegmatis (1, 7).”
BackgroundExtensively Drug-Resistant Tuberculosis
Wilson, J. W., & Tsukayama, D. T. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.01.014 · Cited by 29
Joshi, S. D., Dixit, S. R., Kulkarni, V. H., Lherbet, C., Nadagouda, M. N., & Aminabhavi, T. M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.032 · Cited by 28
Mo, L., Zhang, W., Wang, J., Weng, X. H., Chen, S., Shao, L., Pang, M.-Y., & Chen, Z. W. (2004) · Microbial Drug Resistance · doi:10.1089/mdr.2004.10.269 · Cited by 28
“41 On the other hand, M. tuberculosis KatG func-1 tions as a peroxidase, oxidazing INH from a prodrug chemical to an electrophilic species, which binds to and inactivates InhA, an acyl carrier protein, 1,28 and other targets.”
Cangelosi, G. A., Brabant, W. H., Britschgi, T. B., & Wallis, C. K. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1790 · Cited by 28
“Genotypic methods include proposed PCR assays for the genetic determinants of antibiotic resistance (2, 6, 27, 31).”
MethodFatty Acid Biosynthesis and Oxidation
Zhang, H., Machutta, C. A., & Tonge, P. J. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00668-7 · Cited by 33
Kumar, A., & Siddiqi, M. I. (2008) · Journal of Molecular Modeling · doi:10.1007/s00894-008-0326-8 · Cited by 27
Detecting Novel Genetic Variants Associated with Isoniazid-Resistant Mycobacterium tuberculosis
Shekar, S., Yeo, Z. X., Wong, J. C. L., Chan, M., Ong, D. C. T., Tongyoo, P., Wong, S. Y., & Lee, A. S. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102383 · Cited by 27
Impact of the epoxide hydrolase EphD on the metabolism of mycolic acids in mycobacteria
Madacki, J., Laval, F., Grzegorzewicz, A. E., Lemassu, A., Záhorszká, M., Arand, M., McNeil, M., Daffé, M., Jackson, M., Lanéelle, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000246 · Cited by 29
Faïon, L., Djaout, K., Frita, R., Pintiala, C., Cantrelle, F., Moune, M., Vandeputte, A., Bourbiaux, K., Piveteau, C., Herlédan, A., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112440 · Cited by 27
Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis
Ushtanit, A. I., Kulagina, E. V., Mikhailova, Y., Makarova, M. V., Safonova, S., & Zimenkov, D. V. (2022) · Antibiotics · doi:10.3390/antibiotics11020133 · Cited by 28
Poulton, N. C., Azadian, Z. A., DeJesus, M. A., & Rock, J. M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00904-22 · Cited by 36
The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics
Singh, V., Dziwornu, G. A., & Chibale, K. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00472-3 · Cited by 28
Synthesis and Antimycobacterial Activity of 2,1′-Dihydropyridomycins
Horlacher, O. P., Hartkoorn, R. C., Cole, S. T., & Altmann, K. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300385q · Cited by 27
Abanda, N. N., Djieugoue, Y. J., Lim, E., Pefura-Yone, E. W., Mbacham, W. F., Vernet, G., Penlap, V. M., Eyangoh, S. I., Taylor, D. W., & Leke, R. G. F. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2489-3 · Cited by 27
“As such, use of ETH will not be beneficial to the patient [31].”
MethodEffect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid
Jaiswal, I., Jain, A., Verma, S., Singh, P., Kant, S., & Singh, M. (2017) · Lung India · doi:10.4103/0970-2113.217567 · Cited by 27
“[28] Banerjee et al.[31] reported that the CCCP, VER, DNP, RES and CPZ increases the accumulation of a drug due to inhibition of active efflux.”
BackgroundWheeler, P. R., & ANDERSON, P. M. (1996) · Biochemical Journal · doi:10.1042/bj3180451 · Cited by 27
Coll, P., Aragón, L. M., Alcaide, F., Espasa, M., Garrigó, M., González, J., Manterola, J. M., Orús, P., & Salvadó, M. (2005) · Microbial Drug Resistance · doi:10.1089/mdr.2005.11.107 · Cited by 30
“2,33,35 Mutations in the mabA-inhA regulatory region result in the overexpression of the InhA protein through transcriptional upregulation, 29 and are associated with both INH and ETH resistance.”
The mycobacterial antigens 85 complex – from structure to function and beyond
Daffé, M. (2000) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01844-8 · Cited by 33
Rao, G. S., Vijayakrishnan, R., & Kumar, M. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00722.x · Cited by 29
“It is now well established that InhA is the primary molecular target of isoniazid (INH) (2), the drug that has been the frontline agent for the treatment of TB. INH is a prodrug, which must first be activated by KatG, a catalase-peroxidase, to an acyl radical which covalently binds to the co-substrate for InhA, NADH (…”
BackgroundPadhi, A., Naik, S. K., Sengupta, S., Ganguli, G., & Sonawane, A. (2015) · Microbes and Infection · doi:10.1016/j.micinf.2015.11.007 · Cited by 27
Unissa, A. N., Selvakumar, N., Narayanan, S., Suganthi, C., & Hanna, L. E. (2015) · BioMed Research International · doi:10.1155/2015/257983 · Cited by 26
Leung, G. Y. C., Li, H., Toh, Q. Y., Ng, A. M. ‐., Sum, R. J., Bandow, J. E., & Chen, D. Y. ‐. (2010) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201001281 · Cited by 26
Pagaduan, J. V., & Altawallbeh, G. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.03.003 · Cited by 37
“Inh A gene, which codes for 2-trans-enoyl-acyl carrier protein reductase [61], was identified as important for isoniazid and ethionamide resistance [62].”
BackgroundKakwani, M. D., Desai, N. H. P., Lele, A. C., Ray, M., Rajan, M. G. R., & Degani, M. S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.076 · Cited by 26
Grandgirard, D., Furi, L., Ciusa, M. L., Baldassarri, L., Knight, D. R., Morrissey, I., Largiadèr, C. R., Leib, S. L., & Oggioni, M. R. (2015) · BMC Genomics · doi:10.1186/s12864-015-1544-y · Cited by 35
“aureus FabI inhibitors in clinical trial [2-5].”
BackgroundReview: The Molecular Basis of Resistance in Mycobaterium tuberculosis
Santos, L. C. (2012) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2012.21004 · Cited by 31
“This inhA promoter gene region regulates the expression of the enoyl acyl carrier protein reductase and those mutations may increase the level of protein expression [17,30,41,42].”
BackgroundRani, A., Johansen, M. D., Roquet, F., Kremer, L., Awolade, P., Ebenezer, O., Singh, P., Sumanjit, & Kumar, V. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127576 · Cited by 26
A Bisubstrate Analog Inhibitor of the Carboxyltransferase Component of Acetyl-CoA Carboxylase
Levert, K. L., & Waldrop, G. L. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6576 · Cited by 26
Temesgen, M. M., Mariam, S. H., Airgecho, T., Belachew, E. G., & Aseffa, A. (2015) · Tuberculosis Research and Treatment · doi:10.1155/2015/215015 · Cited by 25
“, to both the first-line drug INH and the second-line drug ethionamide due to a missense mutation in the inhA promoter) [49, 50] renders both antibiotics ineffective (ethionamide is a component of the drug regimen for both MDR and XDR TB patients in Ethiopia [1, 22]).”
BackgroundStudy of clinically used and recently developed antimycobacterial agents
Asif, M. (2011) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-011-0020-8 · Cited by 25
“Indeed, mutations in InhA encoding gene have been already identified in INH-resistance strains (Banerjee et al. 1994) even if they occur less frequently than KatG mutations.”
BackgroundStrategies for potentiation of ethionamide and folate antagonists againstMycobacterium tuberculosis
Wolff, K., & Nguyen, L. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.87 · Cited by 31
Kinjo, T., Koseki, Y., Kobayashi, M., Yamada, A., Morita, K., Yamaguchi, K., Tsurusawa, R., Gülten, G., Komatsu, H., Sakamoto, H., et al. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300571n · Cited by 28
Siu, G. G., Yam, W. C., Zhang, Y., & Kao, R. Y. T. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03277-14 · Cited by 31
“Only a few ( 1%) of them were found to harbor mutations in other genetic regions, such as the structural region of mabA-inhA and katG, that have been validated to be associated with INH resistance in previous allelic-exchange experiments (3, 5, 14), whereas the resistance mechanism of the remaining isolates remained u…”
BackgroundKhosravi, A. D., Goodarzi, H., & Alavi, S. M. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(12)70275-1 · Cited by 25
Mechanisms of Action and Resistance of Antimycobacterial Agents
Karakousis, P. C. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_24 · Cited by 31
Novel compounds targeting InhA for TB therapy
AlMatar, M., Makky, E. A., Var, İ., Kayar, B., & Köksal, F. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.09.001 · Cited by 26
“Furthermore, it has been shown that InhA mutation alone was adequate to confer INH resistance in a successive experiment by the identical group [11].”
BackgroundExploring the Structure and Function of the Mycobacterial KatG Protein Using trans -Dominant Mutants
DeVito, J. A., & Morris, S. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.188-195.2003 · Cited by 27
“Previous reports have clearly shown that INH resistance can map to genetic loci other than katG (1, 19).”
BackgroundKinetic mechanism of NADH‐enoyl‐ACP reductase from Brassica napus
Fawcett, T., Copse, C. L., Simon, J. W., & Slabas, A. R. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02128-1 · Cited by 25
Broussy, S., Coppel, Y., Nguyen, M., Bernadou, J., & Meunier, B. (2003) · Chemistry - A European Journal · doi:10.1002/chem.200204637 · Cited by 27
The Mycobacterial Cell Envelope
Besra, G. S., & Brennan, P. J. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06146.x · Cited by 34
Burguière, A., Hitchen, P. G., Dover, L. G., Dell, A., & Besra, G. S. (2005) · Microbiology · doi:10.1099/mic.0.27938-0 · Cited by 25
Chu, M., Mierzwa, R., Xu, L., Yang, S., He, L., Patel, M., Stafford, J. M., Macinga, D. R., Black, T. A., Chan, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.011 · Cited by 25
Grassi, C. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.9.1211 · Cited by 26
Rotta, M., Pissinate, K., Villela, A. D., Back, D. F., Timmers, L. F. S. M., Bachega, J. F. R., de Souza, O. N., Santos, D. S., Basso, L. A., & Machado, P. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.034 · Cited by 24
Nakanaga, K., Hoshino, Y., Yotsu, R. R., Makino, M., & Ishii, N. (2012) · The Journal of Dermatology · doi:10.1111/1346-8138.12047 · Cited by 28
Mutational and expression analysis of tbnat and its response to isoniazid
Sholto-Douglas-Vernon, C., Sandy, J., Victor, T. C., Sim, E., & van Helden, P. D. (2005) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46153-0 · Cited by 24
“…genes, katG, inhA, kasA, ahpC and ndh, have been detected and related to resistance in many INH-resistant M. tuberculosis clinical isolates characterized to date (Banerjee et al., 1994; Victor et al., 1997, 2002; Musser et al., 1996; Kelly et al., 1997; Mdluli et al., 1998; Lee et al., 2001).”
BackgroundJanardhan, S., John, L., Medarametla, P., Poroikov, V., & Sastry, G. N. (2017) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2017.1398782 · Cited by 24
Modi, P., Patel, S. P., & Chhabria, M. T. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1465852 · Cited by 25
“Development of resistance towards the first line drugs such as isoniazid (INH) and rifampicin is also significant concern (Banerjee et al., 1994).”
Background
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.